Log In
Print
BCIQ
Print
Print this Print this
 

Exenatide-XTEN (VRS-859)

  Manage Alerts
Collapse Summary General Information
Company Amunix Operating Inc.
DescriptionExenatide attached to Amunix's XTEN half-life extension technology for once-monthly dosing
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Mechanism of ActionGlucagon-like peptide-1 (GLP-1) receptor agonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase I
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes; Treat Type II diabetes and
Regulatory Designation

Partner

Diartis Pharmaceuticals Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today